Clinical Study

Volumetric Modulated Arc Therapy of the Pelvic Lymph Nodes to the Aortic Bifurcation in Higher Risk Prostate Cancer: Early Toxicity Outcomes

Table 2

Dose, fractionation schedules, and treatment groups.

Treatment intentPrescription doseNumber of fractionsNumber of patients (%)
No ADTADTTotal

Definitive VMAT
 Intermediate risk74 Gy37549
 High risk78 Gy3911516
 Total6 (5%)19 (17%)25 (22%)
VMAT following HDR brachytherapy50.4 Gy289 (8%)16 (14%)25 (22%)
Salvage VMAT66 Gy3338 (34%)11 (10%)49 (44%)
Adjuvant VMAT 66 Gy 339 (8%)5 (4%)14 (12%)
Total 62 (55%)51 (45%) 113 (100%)